BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.
https://finance.yahoo.com/news/biodelivery-sciences-international-announces-elyxyb-133000908.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.